Development Project | Target | Indications | Modality | Country | Development stage | |||
---|---|---|---|---|---|---|---|---|
Nonclinical | Phase1 | Phase2/3 | Filed | |||||
Nanvuranlat (Development code: JPH203) (Intravenous injection) |
LAT1
|
Biliary tract cancer
|
Low molecular
|
Japan
|
*
|
|||
Nanvuranlat (Development code: JPH203) (Intravenous injection) |
LAT1
|
Biliary tract cancer
|
Low molecular
|
US
|
**
|
|||
Nanvuranlat (Development code: JPH203) (Oral administration) |
LAT1
|
Biliary tract cancer
|
Low molecular
|
Japan and overseas
|
|
|||
Nanvuranlat (Development code: JPH203) Companion diagnostic |
Non disclosure
|
Biliary tract cancer
|
Diagnostic
|
Japan
|
|
|||
OKY-034 (Oral administration) |
LAT1
|
Pancreatic cancer
|
Low molecular
|
Japan
|
|
|||
LAT1 inhibitor (In combination with other agents) |
LAT1
|
Biliary tract cancer/
pancreatic cancer |
Low molecular
|
Japan
|
|
|||
LAT1 inhibitor |
LAT1
|
Autoimmune disease
|
Low molecular
|
US
|
|
|||
NKO-028/035 (PET probe diagnostic) |
LAT1
|
Solid cancer
|
Diagnostic
|
Japan
|
***
|
|||

* Ohara Pharmaceutical will file an application.
** A clinical trial is in preparation now.
*** Clinical research
** A clinical trial is in preparation now.
*** Clinical research